Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cavilon (specifically Cavilon No Sting Barrier Film) is a liquid barrier film developed by 3M that forms a transparent, breathable, and waterproof protective coating on the skin. It is composed of a unique blend of polymers, primarily an acrylate terpolymer, dissolved in a fast-drying, non-stinging solvent system consisting of hexamethyldisiloxane and isooctane. The film is designed to protect intact or damaged skin from body fluids, adhesive trauma, friction, and incontinence-associated dermatitis (IAD). In the context of oncology, it is used prophylactically to reduce the incidence and severity of radiodermatitis in patients undergoing radiotherapy for cancers such as breast cancer. Unlike traditional ointments or creams, it does not require removal and does not interfere with the adhesion of medical tapes or dressings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cavilon No Sting Barrier Film.